ERBB2 and gastric cancer: Based on these observations, the future development of LJM716 is likely to focus on combination with other therapies, and a phase I study of LJM716 in combination with trastuzumab in patients with HER2-overexpressing breast or gastric cancer is currently ongoing (NCT01602406).